Fairvalue-Calculator Fairvalue-Calculator
EN DE

The a2 Milk Company (ACOPF) Fair Value & Analysis

Consumer Defensive · US · Market cap $2.6B

Price$5.00
Fair Value$3.60
Upside-28.0%
Quality94/100
Evidence: High Range $2.94 – $4.51

Analysis

The a2 Milk Company (ACOPF) currently trades at $5.00, while our model-based Fair Value estimate is $3.60 — implying the stock looks roughly 28.0% overvalued today. We read business quality at 94/100 (high quality), in the Consumer Defensive sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

The a2 Milk Company Limited, together with its subsidiaries, sells A2-type protein type branded milk and related products in Australia, New Zealand, China, rest of Asia, and the United States. The company offers infant milk formula; other nutritional products and milk; manufactures and sells nutritional and ingredients products, as well as provides rent, royalty, and licensing services. It offers its products under the a2 Milk and a2 Platinum brands. The company was formerly known as A2 Corporation Limited and changed its name to The a2 Milk Company Limited in April 2014. The a2 Milk Company Limited was incorporated in 2000 and is based in Auckland, New Zealand.

Open the full interactive analysis →

Similar stocks

Nestlé S.A (NSRGF) -33% Foshan Haitian Flavouring and Food Company (603288) -28% Nestlé India Limited (NESTLEIND) -75% Grupo Bimbo, S.A. (BIMBOA) -21% Uni-President Enterprises Corp (1216) -27% Britannia Industries Limited (BRITANNIA) -62%

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.